CR7152A - Un inhibidor de pde4 y un agente de anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias. - Google Patents

Un inhibidor de pde4 y un agente de anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias.

Info

Publication number
CR7152A
CR7152A CR7152A CR7152A CR7152A CR 7152 A CR7152 A CR 7152A CR 7152 A CR7152 A CR 7152A CR 7152 A CR7152 A CR 7152A CR 7152 A CR7152 A CR 7152A
Authority
CR
Costa Rica
Prior art keywords
agent
polinergic
pde4 inhibitor
obstructive diseases
combination anti
Prior art date
Application number
CR7152A
Other languages
English (en)
Inventor
W Watson John
A Armstrong Roisin
Yeadon Michael
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0129396A external-priority patent/GB0129396D0/en
Priority claimed from GB0210240A external-priority patent/GB0210240D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of CR7152A publication Critical patent/CR7152A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se relaciona con una combinacion de un inhibidor selectivo de PDE4 y un agente anticolinergico para la administracion simultanea, secuencial o por separado por la via inhalada en el tratamiento de una enfermedad obstructiva de las vias respiratorias u otras enfermedades inflamatorias, con la condicion de que el agente anticolinergico no sea una sal de tiotropio
CR7152A 2001-05-25 2003-11-19 Un inhibidor de pde4 y un agente de anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias. CR7152A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29360601P 2001-05-25 2001-05-25
GB0129396A GB0129396D0 (en) 2001-12-07 2001-12-07 Pharmaceutical combination
GB0210240A GB0210240D0 (en) 2002-05-03 2002-05-03 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
CR7152A true CR7152A (es) 2004-02-23

Family

ID=27256347

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7152A CR7152A (es) 2001-05-25 2003-11-19 Un inhibidor de pde4 y un agente de anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias.

Country Status (25)

Country Link
US (1) US20040147544A1 (es)
EP (1) EP1395288A1 (es)
JP (1) JP2005508861A (es)
KR (1) KR20040007605A (es)
CN (1) CN1511042A (es)
AP (1) AP2003002909A0 (es)
BG (1) BG108382A (es)
BR (1) BR0209992A (es)
CA (1) CA2446613A1 (es)
CO (1) CO5640041A2 (es)
CR (1) CR7152A (es)
CZ (1) CZ20033150A3 (es)
EE (1) EE200300585A (es)
HU (1) HUP0400037A2 (es)
IL (1) IL158776A0 (es)
MA (1) MA27027A1 (es)
MX (1) MXPA03010162A (es)
NO (1) NO20035204D0 (es)
NZ (1) NZ529335A (es)
OA (1) OA12610A (es)
PA (1) PA8546001A1 (es)
PL (1) PL367085A1 (es)
SK (1) SK14312003A3 (es)
TN (1) TNSN03123A1 (es)
WO (1) WO2002096463A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20040058950A1 (en) * 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
DE10230769A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren
WO2004084896A1 (en) * 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
CA2519682A1 (en) * 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
RU2006132043A (ru) * 2004-02-06 2008-03-20 МЕДА Фарма ГмбХ унд Ко.КГ (DE) Комбинация и фармацевтический препарат для лечения ринита
ES2413011T3 (es) 2004-02-06 2013-07-15 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
EP1713471B1 (en) * 2004-02-06 2012-01-18 MEDA Pharma GmbH & Co. KG Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
WO2005102344A1 (ja) * 2004-04-27 2005-11-03 Kyowa Hakko Kogyo Co., Ltd. 医薬組成物
EP1634595B1 (en) * 2004-08-19 2008-08-13 Rottapharm S.p.A. N-Phenylbenzamide derivatives as drugs for the treatment of Chronic Obstructive Pulmonary Disease (COPD)
EP1863476B1 (en) 2005-03-16 2016-02-03 MEDA Pharma GmbH & Co. KG The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
KR100696432B1 (ko) * 2005-08-31 2007-03-19 김용환 건강진단용 팬티
BRPI0617673C1 (pt) * 2005-10-19 2012-05-22 Ranbaxy Lab Ltd composições de inibidores de fosfodiesterase do tipo iv
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
NZ591969A (en) 2005-12-21 2012-05-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-adrenoceptor agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552407A (en) * 1993-06-11 1996-09-03 New York University Medical Center Anhydroecgonine compounds and their use as anticholinergic agents
ES2172583T3 (es) * 1995-06-06 2002-10-01 Pfizer 5,6-dihidro-9h-pirazol(3,4-c)-1,2,4-triazol(4,3-alfa)piridinas triciclicas.
US20020193393A1 (en) * 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors

Also Published As

Publication number Publication date
CA2446613A1 (en) 2002-12-05
KR20040007605A (ko) 2004-01-24
NO20035204D0 (no) 2003-11-24
IL158776A0 (en) 2004-05-12
WO2002096463A1 (en) 2002-12-05
AP2003002909A0 (en) 2003-12-31
JP2005508861A (ja) 2005-04-07
BG108382A (bg) 2004-12-30
CZ20033150A3 (cs) 2004-06-16
CN1511042A (zh) 2004-07-07
NZ529335A (en) 2005-09-30
MXPA03010162A (es) 2004-03-10
OA12610A (en) 2006-06-09
EP1395288A1 (en) 2004-03-10
US20040147544A1 (en) 2004-07-29
PA8546001A1 (es) 2003-12-30
HUP0400037A2 (hu) 2004-04-28
PL367085A1 (en) 2005-02-21
SK14312003A3 (sk) 2004-08-03
MA27027A1 (fr) 2004-12-20
CO5640041A2 (es) 2006-05-31
TNSN03123A1 (en) 2005-12-23
EE200300585A (et) 2004-04-15
BR0209992A (pt) 2004-04-06

Similar Documents

Publication Publication Date Title
CR7152A (es) Un inhibidor de pde4 y un agente de anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias.
CO5540324A2 (es) Un agonista de a2a en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas
ECSP034620A (es) Mezclas o compuestos organicos para el tratamiento de enfermedades de las vias respiratorias
CL2004001170A1 (es) Combinacion farmaceutica inhalable que contiene (a) formoterol, o una sal, o un solvato de el o de la sal y (b) furoato de mometasona; estuche farmaceutico que la comprende; y su uso en la terapia de una enfermedad inflamatoria u obstructiva de las v
BR0008039A (pt) Combinações de formoterol e um sal de tiotrópio
CO5550426A2 (es) Novedoso metodo terapeutico
BR0307050A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, sal farmaceuticamente aceitável, e, uso de um composto ou sal
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
CO4340692A1 (es) Furoato de mometasona para el tratamiento de las enfermeda- des pulmonares y de vias respiratorias
CY1106430T1 (el) Φαρμακα για εισπνοη που πepιλαμβανουν βηταμιμητικα και αντιχολινepγικο
DOP2003000585A (es) Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades
AR058194A1 (es) Medicamentos que comprenden un agente antimuscarinico y un corticoesteroide
MXPA03011702A (es) Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias.
BR0206549A (pt) Uso de flumazenil na produção de uma droga para o tratamento de dependência de álcool
AR057904A1 (es) Medicamentos que comprenden un agente antimuscerinico y un corticoesteroide
DK1220676T3 (da) Forebyggelse af colorektal cancer
PY0212139A (es) Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias
UY27307A1 (es) Un inhibidor de pde4 y un agente anticolinérgico en combinación para tratar enfermedades obstructivas de vías respiratorias
AR022348A1 (es) Una composicion farmaceutica para el tratamiento de los sintomas del tracto urinario inferior
PY0212140A (es) UN AGONISTA DE A2a EN COMBINACION CON UN AGENTE ANTICOLINERGICO PARA EL TRATAMIENTO DE ENFERMEDADES OBSTRUCTIVAS DE LAS VIAS AEREAS
BRPI0508053A (pt) método de combater toxicidade causada por um composto antifolato, e de tratar uma doença, usos de enzima que possui atividade de carbóxi-peptidase g, de composto antifolato, de agente de resgate de rota de folato, e de enzima que possui atividade de carbóxi-peptidase g e de um agente de resgate de rota de folato, sistema terapêutico, e, método ex vivo de clivar um grupo l-glutamato terminal de um composto, de determinar a taxa e/ou extenção de clivagem de um composto, e de clivagem de um composto
ECSP045142A (es) Combinacion farmaceutica
CO5590922A2 (es) Uso de istradefilina (kw-6002) para el tratamiento de trastornos de la conducta
HRP20050580A2 (en) Synergistic combination comprising roflumilast and (r,r)-formoterol
DE502005001659D1 (de) Schleimdrogenbasierte Lutschtablette gegen entzündliche Erkrankungen des Mund- und Rachenraums

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)